Notice

Competition: point of care diagnostics at the front line

£500k is available to fund the development of novel PoC diagnostics devices.

• From: Defence and Security Accelerator and Defence Science and Technology Laboratory
• Published: 22 July 2019
• Last updated: 30 July 2019 — See all updates

Documents

Competition document: point of care diagnostics at the front line

HTML

Point of Care diagnostics at the Front Line SC (Innovation) - Terms

PDF, 261 KB, 7 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email accelerator@dstl.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Point of Care diagnostics for the Front Line SC (Innovation) - Schedules

PDF, 236 KB, 10 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email accelerator@dstl.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The Defence and Security Accelerator (DASA) is seeking proposals for innovative ‘Point of Care’ (PoC) diagnostics technologies that provide information to enable clinicians and medical professionals to provide earlier diagnosis and ultimately improve the treatment and long-term health outcomes of individuals exposed to chemical and biological hazards.

Technologies that enable rapid diagnosis of individuals exposed to biological or chemical agents are currently limited. They are time-consuming, resource intensive, provide a limited identification capability and frequently rely on reach back to laboratory facilities to achieve a high confidence output. Development of novel, enhanced PoC diagnostic devices that can be used rapidly, as close to the patient as possible, and potentially in austere locations represent an attractive solution to this problem.

Total funding of up to £500k is available for this phase to fund multiple proposals at a range of Technology Readiness Levels (up to TRL 6). Additional funding for further phases of work to develop lower TRL technologies towards a higher TRL is potentially available. Full details are available in the competition document.

The competition closes at midday (BST) on 26 September 2019 .

Queries should be sent to accelerator@dstl.gov.uk.

Published 22 July 2019
Last updated 30 July 2019 + show all updates

1. 30 July 2019

   Please note we have changed our preference for those platforms aiming to detect specific nucleic acid analytes; Staphylococcus aureus NCTC 10788 should be used instead of the previously stated Bacillus subtilis subsp. Spizizenii.

2. 22 July 2019

   First published.